Clinical trial · Observational
Disitamab Vedotin (RC48-ADC) in Breast Cancer
Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real-world Study
NCT05851677CI-TRIAL-00095315recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Disitamab vedotin | Drug | Disitamab Vedotin | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- RC48-ADC
- description
- RC48-ADC for breast cancer
- interventionNames
- Drug: Disitamab vedotin
Primary outcomes (1)
- measure
- Progression-Free Survival
- timeFrame
- From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)
- description
- The time from the date of starting Disitamab Vedotin to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.
Secondary outcomes (1)
- measure
- Adverse events
- timeFrame
- From the date of starting Disitamab vedotin to the end of the treatment (up to approximately 1 year)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed breast cancer; * Prior or current use of Disitamab vedotin (RC48-ADC); Exclusion Criteria: * Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
References
Publications (0)
Data not yet available
No reference posted for this study.